Jul 12, 2004 by Brian GormanIndia Woos U.S. Biotech CompaniesBusiness abroad would bode well for investors and consumers.
Jul 9, 2004 by Brian GormanClothier Measures Up in JuneWhile other retailers struggle, catalog and Internet business have strengthened JoS. A. Bank.
Jul 9, 2004 by Brian GormanYahoo!'s Star PowerYahoo!'s growing success in capturing entertainment ad dollars is a promising sign.
Jul 8, 2004 by Brian GormanSouthwest Shows No MercyIt continues to pressure other airlines even as high fuel prices dampen profits.
Jul 7, 2004 by Brian GormanCrude Near CubaHow will Repsol's findings affect energy reserves, U.S. policies, and the Cuban populace?
Jul 7, 2004 by Brian GormanMiddle East Payoff?Middle East reforms could present an opportunity for a few risk-taking companies.
Jul 7, 2004 by Brian GormanAcusphere Makes a FriendThe struggling specialty pharmaceutical company has shown an ability to survive, which may serve it well.
Jul 6, 2004 by Brian Gorman3M's Pharma Push3M's Aldara may draw the firm into the drug manufacturers' blockbuster trap.
Jul 6, 2004 by Brian GormanHidden Drug CostsRegulatory requirements play an important role in drug expenses.
Jul 2, 2004 by Brian GormanMuscle in Wyeth's PipelineAn early stage Wyeth drug may have a better-than-average chance of approval.
Jul 2, 2004 by Brian GormanAttention Sony Shoppers!Sony plans to expand its retail store presence in the U.S.
Jul 1, 2004 by Brian GormanCharles River's Big BuyThe purchase of Inveresk is being viewed skeptically, but may have benefits lacking in past acquisitions.
Jun 30, 2004 by Brian GormanViacom's Sterner StuffEven as tougher indecency legislation is passed, Viacom may see Howard Stern as anything but a liability.
Jun 22, 2004 by Brian GormanADM's Bean CountingADM is positioned to benefit from China's growth as a consumer of imported soybean oil.
Jun 22, 2004 by Brian GormanMore Green for MonsantoThe full-year earnings may not please everyone, but the company plants roots for long-term success.
Jun 22, 2004 by Brian GormanDick's Play for Galyan'sDick's Sporting Goods purchase of Galyan's may worry some investors.
Jun 21, 2004 by Brian GormanClinical Trials ControversyA clinical trials database may appeal to some. But open access to studies may not be in the interests of drug companies or the public.
Jun 21, 2004 by Brian GormanGenzyme's Growth ConceptionGenzyme's Seprafilm product could see growth with the increase in C-sections.
Jun 18, 2004 by Brian GormanLockheed's Weight ProblemProblems with Lockheed Martin's JSF program may leave investors feeling vulnerable.
Jun 18, 2004 by Brian GormanCoke's European TuneApple may be a threat to Coke's dominance in Europe's music download space, but iTunes is no shoo-in.
